Vir Biotechnology (NASDAQ: VIR)
Vir Biotechnology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vir Biotechnology Company Info
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
News & Analysis
Vir (VIR) Q2 Revenue Drops 61%
Is Vir Biotechnology Stock a Buy?
The biotech is out to prove that it isn't just a "pandemic stock."
Why Shares of Vir Biotechnology Are Plunging Thursday
The company had disappointing trial news for one of its lead therapies.
2 Stocks That Could Turn $100 Into $1,000 by 2028
These growth stocks have substantial tailwinds.
2 Fast-Growing Healthcare Stocks to Buy and Hold
The innovative companies have made great gains in a short period of time.
Why Vir Biotechnology Jumped Nearly 19% Today
A COVID-19 partnership with a major drugmaker is producing more fruit than expected.
Why Shares of Vir Biotechnology Rose 20.4% This Week
Joining the S&P SmallCap 600 could boost the company's profile.
Why Vir Biotechnology Stock Is Skyrocketing Today
The S&P SmallCap 600 index will soon include Vir.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.